Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. reports on the Annual Meeting of Shareholders held on June 16, 2026. The filing covers corporate governance actions, including director elections, executive compensation approvals, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder voting results and corporate governance matters.
Material Changes and Voting Results
Shareholders representing approximately 16% of the total outstanding ordinary shares (2,544,796,000 shares) attended the meeting, constituting a quorum. All eight proposals presented were approved by the shareholders:
- Director Elections: Re-election of Mr. Sam Moed, Dr. Yael Margolin, and Mr. Adi Raviv to the Board of Directors.
- Capital Structure: Approval to amend the Articles of Association to increase the number of authorized Ordinary Shares.
- Executive Compensation: Approval of an amendment to the employment agreement and a 2026 long-term restricted share unit (RSU) grant for CEO Amir Reichman.
- Board Compensation: Approval of an extension to the service agreement and a special RSU grant for Chairman Mark Germain.
- Auditor Ratification: Appointment of Zvi Haft (BDO) as the Company's auditors for 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document is limited to the procedural outcomes of the shareholder meeting.
Key Facts for Investor Verification
- Verify the impact of the increased authorized share count on potential future dilution.
- Review the specific terms of the amended employment agreement for CEO Amir Reichman and the valuation of the approved RSU grants.
- Confirm the details of the special RSU grant awarded to Chairman Mark Germain for "special recent efforts."
- Check subsequent filings for the Company's financial performance, as this 6-K contains no financial data.